Aplastic anaemia in donor cells 14 years after bone-marrow transplant

Melenhorst, J. Joseph; Luxemburg-Heijs, S A van; Landegent, J. E.; Willemze, L Roel; Fibbe, Willem E.; Falkenburg, J.H.F.

doi:10.1016/s0140-6736(99)01926-1

Cited by 7 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytotoxic ␥␦ + T cells have been generated against EBV-transformed B cells, 21 Burkitt lymphoma cells, 21 Daudi lymphoma cells, 22 and against autologous maturing hematopoietic cells from a patient with aplastic anemia. 23 FBS was no longer used in cultures after patient No. 5 to avoid the possibility of presenting xenogeneic antigens from FBS to CD8 + ␥␦ T cells, resulting in activation and proliferation.…”

Section: Discussionmentioning

confidence: 99%

Human γδ+ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response

Lamb

Musk

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Refractory acute lymphoblastic leukemia (ALL) is often incurable, and relapse rates following allogeneic bone marrow transplantation (BMT) remain high. We have reported that patients who develop increased numbers of ␥␦ + T cells soon after BMT are significantly less likely to relapse. We now show in seven donor/recipient pairs that donor-derived V␦1 + CD4 − CD8 − ␥␦ + T cells are activated and proliferate in response to recipient primary ALL blasts. In addition, these cells have been shown to bind and lyse the recipient ALL blasts. Separately, ␥␦ + T cells proliferate poorly or not at all in mixed lymphocyte culture against HLA-mismatched unrelated stimulator cells. These observations suggest that allogeneic ␥␦ + T cells could be an effective immunotherapeutic strategy against refractory disease without the risk of graft-versus-host disease. Bone Marrow Transplantation (2001) 27, 601-606.

show abstract

Section: Discussionmentioning

confidence: 99%

Human γδ+ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response

Lamb

Musk

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…2, 26 The ratio of BMMNCs to T cells during the incubation phase was 1:3 for the V␤-expanded CD8 ϩ T cells and 1:18 for the non-V␤-expanded CD8 ϩ T cells.…”

Section: Trisomy 8 Colony Inhibition Assaymentioning

confidence: 93%

“…These T-cell lines were then tested for clonogenic hematopoietic progenitor cell lysis (bottom left panel): Autologous BMMNCs were incubated for 4 hours with the (25 Gy-irradiated) expanded T cells (BM ϩ T INC) before plating in semisolid medium containing cytokines to support hematopoietic progenitor cell growth. 26 WT1 specificity of the T-cell lines was assessed in this assay by pulsing the BMMNCs with the WT1 peptide library before this 4-hour preincubation (BM ϩ T ϩ WT1 INC). As a negative control, we incubated T cells and BMMNCs separately before mixing and plating (BM ϩ T NO INC).…”

mentioning

confidence: 99%

T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy

Sloand

Melenhorst

Tucker

et al. 2011

Blood

View full text Add to dashboard Cite

Clinical observations and laboratory evidence link bone marrow failure in myelodysplastic syndrome (MDS) to a T cellmediated immune process that is responsive to immunosuppressive treatment (IST) in some patients. Previously, we showed that trisomy 8 MDS patients had clonally expanded CD8 ؉ T-cell populations that recognized aneuploid hematopoietic progenitor cells (HPC). Furthermore, microarray analyses showed that Wilms tumor 1 (WT1) gene was overex-

show abstract

“…Donor and patient PHA blasts and donor derived EBV-LCL, either unpulsed or pulsed with CMV pp65 or adenovirus hexon pepmixes, were used as targets of the T cell line in a standard 51 Cr release assay as described. 35 The targets were incubated with the T cell line at 40:1, 20:1, 10:1, and 5:1 ratios for 4 hours, after which supernatants were harvested to determine the amount of 51 Cr with a scintillation counter. Spontaneous and maximum 51 Cr release were determined by culturing the 51 Cr loaded targets alone and in the presence of Triton X-100, respectively.…”

Section: Methodsmentioning

confidence: 99%

Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells

et al. 2015

View full text Add to dashboard Cite

A 12-year-old boy with refractory acute lymphoblastic leukemia received a haploidentical transplant from his mother. As prophylaxis for Epstein-Barr virus (EBV), cytomegalovirus (CMV) and adenovirus, he received ex vivo expanded virus-specific donor T cells 3.5 months after transplant. Four weeks later leukemic blasts bearing the E2A deletion, identified by fluorescent in situ hybridization (FISH), appeared transiently in the blood followed by a FISH-negative hematological remission, which was sustained until a testicular relapse 3.5 months later. Clearance of the circulating leukemic cells coincided with a marked increase in circulating virus-specific T cells. The virus-specific cytotoxic T-cell (CTL) line showed strong polyfunctional reactivity with the patient's leukemic cells but not phytohemagglutinin (PHA) blasts, suggesting that virus-specific CTL lines may have clinically significant antileukemia activity.

show abstract

Aplastic anaemia in donor cells 14 years after bone-marrow transplant

Cited by 7 publications

References 6 publications

Human γδ+ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response

Human γδ+ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response

T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy

Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells

Contact Info

Product

Resources

About